Status:
COMPLETED
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atopic Dermatitis
Dermatitis, Atopic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Moderate atopic dermatitis patients (IGA=3).
- The disease involvement must be \>5% of body surface area.
- Female patients of child-bearing potential must use an appropriate method of contraception.
- Exclusion criteria:
- Patients with any active skin disease other than atopic dermatitis will not be eligible.
- Patients who have had systemic treatment for atopic dermatitis or other topical or transdermal treatments (such as nicotine, hormone replacement therapies) within 14 days prior to first application of study medication and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 10 days prior to first application and/or oral anti-histamines within 5 days of the first dose.
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00354510
Start Date
March 1 2006
Last Update
June 4 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Augsburg, Bavaria, Germany, 86179
2
GSK Investigational Site
Mahlow, Brandenburg, Germany, 15831
3
GSK Investigational Site
Hamburg, Hamburg, Germany, 20246
4
GSK Investigational Site
Hamburg, Hamburg, Germany, 20249